Q-omics provides the consensus-scored IYD profile across patient tissues and cancer cell-line models. IYD expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IYD is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, IYD protein abundance shows 15,296 significant protein co-abundance associations, with the highest sampling consensus in COAD. Together, these results highlight KIRC, and COAD as cancer lineages where IYD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IYD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IYD survival associations across molecular data types. IYD RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IYD RNA expression–survival associations across cancer types. High IYD expression shows unfavorable associations in ACC, DLBC and BRCA, but favorable associations in KIRC, LIHC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IYD RNA expression.
This table summarizes IYD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IYD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IYD shows lower tumor expression in KIRC, THCA, KIRP, LIHC, KICH and LUSC. The KIRC box plot shows higher IYD RNA expression in normal versus tumor tissue (log2 FC = −2.123, t-test p < 0.001).
This table shows molecular features associated with IYD in patient tissues and cancer cell lines. In patient samples, IYD shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, IYD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
